肝细胞癌RNA结合蛋白功能和预后价值系统分析*

doi:10.3969/j.issn.1672-5069.2022.05.022

Abstract

Abstract: Objective Based on the cancer genome atlas (TCGA) database, we conducted a systematic bioinformatics analysis of abnormal cancerous RNA binding proteins (RBPs) in patients with hepatocellular carcinoma (HCC), with the aim of identifying the prognostic markers and potential therapeutic targets. Methods The cancerous and adjacent liver tissue HCC RNA sequencing data was downloaded from TCGA database, and the functional enrichment analysis and visualization of interaction relationships among them were performed. The univariate and multivariate Cox regression analyses were subsequently applied to identify RBPs that were significantly related to the prognosis and a prognostic model was constructed. The predictive performance of the prognostic model was evaluated by survival analysis and receiver operating characteristic (ROC) curve and was verified in the test cohort. The human protein atlas online database was applied to verify the RBP levels in the prognostic model. Results A total of 82 differentially expressed RBPs were identified, including 55 up-regulated and 27 down-regulated (FDR< 0.05 and |log2 FC|>1); the further functional enrichment and interaction analyses showed that the differentially expressed RBPs were mainly related to regulation of mRNA metabolic process, RNA catabolic, mRNA catabolic process, and macromolecule methylation; five RBP genes, e.g., the LIN28B, SMG5, PPARGC1A, LARP1B, and ANG were identified as prognostic-related genes and were used to construct the prognostic model; the predictive ability of the prognostic model was verified in the test cohort; the ROC curve analysis showed that the prognostic model had good sensitivity and specificity; the independent prognostic analysis showed that the risk score could be an independent prognostic factor for patients with HCC. Conclusion The constructed prognostic prediction model by analyzing the differentially expressed RBPs in cancerous tissues in patients with HCC is reliable, which might be served as a prognostic biomarkers and therapeutic targets.

Key words: Hepatocellular carcinoma, RNA-binding proteins, Prognostic model, Prediction, Cancer genome atlas database

Wu Tong, Zhang Qiaoli, Qi Xuewei. Systematic analysis of functions of RNA-binding proteins in hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2022, 25(5): 693-697.

References

[1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin,2020, 70(1):7-30.
[2]Zhou XT, Ding J, Li HY, et al. Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma. J Cell Mol Med,2020, 24(7):4298-4311.
[3]Masuda K, Kuwano Y. Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers. Wiley Interdiscip Rev RNA, 2019,10(3):e1520.
[4]Sebestyén E, Singh B, Miñana B, et al. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res,2016,26(6):732-744.
[5]Jiang Y, Zhang M, Qian Y, et al. Rbm24, an RNA-binding protein and a target of p53, regulates p21 expression via mRNA stability. J Biol Chem,2014, 289(6):3164-3175.
[6]Nakka KK, Chaudhary N, Joshi S, et al. Nuclear matrix-associated protein SMAR1 regulates alternative splicing via HDAC6-mediated deacetylation of Sam68. Proc Natl Acad Sci U S A,2015,112(26):E3374-3383.
[7]Legrand N, Dixon DA, Sobolewski C. AU-rich element-binding proteins in colorectal cancer. World J Gastrointest Oncol,2019,11(2):71-90.
[8]Chatterji P, Rustgi AK. RNA binding proteins in intestinal epithelial biology and colorectal cancer. Trends Mol Med,2018,24(5):490-506.
[9]Huang X, Zhang H, Guo X, et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol,2018,11(1):88.
[10] Palanichamy JK, Tran TM, Howard JM, et al. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest,2016,126(4):1495-1511.
[11] Zhao Q, Caballero OL, Davis ID, et al. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res,2013, 19(9):2460-2472.
[12] Zheng L, Zhang Z, Zhang S, et al. RNA binding protein RNPC1 inhibits breast cancer cell metastasis via activating STARD13-correlated ceRNA network. Mol Pharm,2018,15(6):2123-2132.
[13] Hopkins TG, Mura M, Al-Ashtal HA, et al. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucl Acids Res,2016,44(3):1227-1246.
[14] Wurth L, Papasaikas P, Olmeda D, et al. UNR/CSDE1 drives a post-transcriptional program to promote melanoma invasion and metastasis. Cancer Cell,2016, 30(5):694-707.
[15] Sanchcz-Jimenez C, Ludena M D, Izquierdo J M. T-cell intracellular antigens function as tumor suppressor genes. Cell Death Dis,2015,6:e1669.
[16] Li M, Wang J, Yang L, et al. eRF3b, a biomarker for hepatocellular carcinoma, influences cell cycle and phosphoralation status of 4E-BP1. PLoS One,2014,9(1):e86371.
[17] Zhang T, Ma Z, Liu L, et al. DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway. Cell Death Dis, 2018,9(6):675.
[18] Hatanaka T, Higashino F, Tei K, et al. The neural ELAVL protein HuB enhances endogenous proto-oncogene activation. Biochem Biophys Res Commun,2019, 517(2):330-337.
[19] Zhao WS, Yan WP, Chen DB, et al. Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma. Am J Cancer Res,2019,9(6):1183-1200.
[20] Huang X, Zhang H, Guo X, et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol,2018,11(1):88.
[21] Chung KY, Cheng IK, Ching AK, et al. Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition. Hepatology,2011,54(1):307-318.
[22] Qi J, Yu Y, Akilli Öztürk Ö, et al. New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals. Gut,2016,65:1690-1701.
[23] Ren H, Xu Y, Wang Q, et al. E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway. Oncotarget,2017, 9(13):10880-10890.
[24] Lu Y, Liu Y, Liao S, et al. Epigenetic modifications promote the expression of the orphan nuclear receptor NR0B1 in human lung adenocarcinoma cells. Oncotarget,2016,7(28):43162-43176.
[25] Jiang HL, Xu D, Yu H, et al. DAX-1 inhibits hepatocellular carcinoma proliferation by inhibiting β-catenin transcriptional activity. Cell Physiol Biochem,2014,34(3):734-742.
[26] Tian N, Shangguan W, Zhou Z, et al. Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma. J Cancer,2019,10(24):6074-6087.
[27] Kannan K, Wang L, Wang J, et al. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci U S A, 2011,108(22):9172-9177.
[28] Zhang S, Jiang J, Chen Z, et al. Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population. Onco Targets Ther,2018,11:4651-4660.
[29] Stavraka C, Blagden S. The La-related proteins, a family with connections to cancer. Biomolecules,2015,5(4):2701-2722.
[30] Chen Y, Wu Y, Zhang X, et al. Angiopoietin-2 (Ang-2) is a useful serum tumor marker for liver cancer in the Chinese population. Clin Chim Acta,2018, 478:18-27.

Systematic analysis of functions of RNA-binding proteins in hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tang Lei, Peng Lei, Ye Jun, et al. Multivariate analysis of liver fibrosis progress in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(4): 538-541.
[2]	Bu Fan, Chai Jianbo, Bai Bing, et al. Cyber-based study on ferroptosis-related long non-coding RNA signature predicting prognosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(4): 558-562.
[3]	Luo Ke, Ding Li, Liu Mei. Serum miR-21 and miR-148b levels in patients with chronic hepatitis B and their predictive value for liver tissue inflammation grading and fibrosis staging [J]. Journal of Practical Hepatology, 2022, 25(3): 335-338.
[4]	Zhang Lan, Li Yan, Yang Ning, et al. Clinical application of blood red blood cell distribution width and neutrophil to lymphocyte ratio in evaluating liver damage in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2022, 25(3): 367-370.
[5]	Yang Ruixu, Fan Jiangao. Epidemiology and screening of nonalcoholic fatty liver disease-related hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(2): 153-156.
[6]	Zhang Jian, Chen Yu, Duan Zhongping. Serum FT3 level changes in patients with HBV-ACLF [J]. Journal of Practical Hepatology, 2022, 25(2): 239-242.
[7]	Yu Tao, Fu Lulu, Chen Fang, et al. Clinical value of perfusion phase analysis of contrast-enhanced ultrasound in the diagnosis of patients with hyperplastic nodules with underlying liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(2): 267-270.
[8]	Yan Jingquan, Wang Chunling, Liu Juan, et al. Predictive value of antiviral response by serum hepatitis B virus pregenomic RNA levels in naïve patients with hepatitis B receiving nucleos(t)ide analogues treatment [J]. Journal of Practical Hepatology, 2022, 25(1): 22-25.
[9]	Xiao Qian, Zhou Zhan, Hu Xiaoli. Clinical application of contrast-enhanced ultrasound parameters in the quantitative diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(1): 92-95.
[10]	Expert Group for Project of Hepatocellular Carcinoma Screening and Surveillance, Chinese Foundation for Hepatitis Prevention and Control. Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection [J]. Journal of Practical Hepatology, 2021, 24(6): 776-785.
[11]	Wu Huijuan, He Nian'an, Xie Li, et al. Contrast-enhanced ultrasonography and serum CA19-9 levels in differential diagnosis of patients with intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(6): 903-906.
[12]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Predicting value of serum ascites albumin gradient on esophageal variceal bleeding risk in patients with decompensated hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(5): 637-640.
[13]	Liang Xu, Liu Yuanyuan, Yang Xuegang, et al. Computed tomography and magnetic resonance imaging in the diagnosis of patients with hepatocellular carcinoma based on liver imaging report data system v2018 [J]. Journal of Practical Hepatology, 2021, 24(5): 725-728.
[14]	Zhao Yi, Lu Bingjiu. UCK2, PRIM1 and DNTM1 levels in cancerous tissues of patients with hepatocellular carcinoma based on TCGA database [J]. Journal of Practical Hepatology, 2021, 24(5): 729-732.
[15]	Zhang Ying, Zhang Lei, Ding Haitao. Impacting efficacy factors of apatinib maintaining treatment after transcatheter hepatic artery chemoembolization in patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(5): 733-736.